当前位置：杭州昊鑫生物科技股份有限公司>>MCE>>生物试剂>> HY-18739佛波醇12-十四酸酯13-乙酸酯
| CAS号 | 16561-29-8 | 产地 | 进口 |
|---|---|---|---|
| 级别 | 其他 |
佛波醇12-十四酸酯13-乙酸酯
注：本产品仅用于科研，不可用于临床
生物活性
Phorbol 12-myristate 13-acetate (PMA), a phorbol ester, is a dual SphK and protein kinase C (PKC) activator[1][2]. Phorbol 12-myristate 13-acetate is a NF-κB activator. Phorbol 12-myristate 13-acetate induces differentiation in THP-1 cells
IC50 & Target
PKC 11.7 nM (EC50) | NF-κB
|
体外研究
(In Vitro)
In order to examine the role of PKC in p38MAPK phosphorylation, the cells are stimulated with the PKC activator, PMA (100 nM), which mimics the binding of DAG, the natural activator of PKC, to the C1 region of the PKCs. p38MAPK phosphorylation by PMA is observed in the two cell types similar to that observed by GnRH in αT3-1 cells, that is, a slow sustained activation (3.2-fold and 3.6-fold, respectively at 30 min). The paradoxical findings that PKCs activated by GnRH and PMA play a differential role in p38MAPK phosphorylation may be explained by differential localization of the PKCs. Basal, GnRH- and PMA- stimulation of p38MAPK phosphorylation in αT3-1 cells is mediated by Ca2+ influx via voltage-gated Ca2+ channels and Ca2+ mobilization, while in the differentiated LβT2 gonadotrope cells it is mediated only by Ca2+ mobilization[2].
THP-1 cells are differentiated into macrophage-like cells (THP-1 macrophages) by incubation in the presence of PMA (200 ng/mL; 1-5 days), which leads to a macrophage-like phenotype characterized by changes in morphology and increased cell surface expression of CD11 and CD14[3].
In the monocytic cell line THP-1, PMA results in a more differentiated phenotype than VD3, according to adherence, loss of proliferation, phagocytosis of latex beads, and expression of CD11b and CD14[5].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)
PMA is a PKC agonist, which reverses the damage induced by 5-hydroxydecanoic acid (5-HD). Thus, activation of the mitoKATP protected mitochondrial function in SOD and MDA via the PKC pathway[4].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量
616.83
性状
Solid
Formula
C36H56O8
中文名称
佛波醇12-十四酸酯13-乙酸酯；(12-)十四酸佛波酯(-13-)乙酸盐；佛波酯
溶解性数据
DMSO : 100 mg/mL (162.12 mM; Need ultrasonic)
Ethanol : 100 mg/mL (162.12 mM; Need ultrasonic)
| 浓度溶剂体积质量 | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6212 mL | 8.1060 mL | 16.2119 mL |
| 5 mM | 0.3242 mL | 1.6212 mL | 3.2424 mL |
| 10 mM | 0.1621 mL | 0.8106 mL | 1.6212 mL |
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (4.05 mM); Clear solution
请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (4.05 mM); Suspended solution; Need ultrasonic
请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.05 mM); Clear solution
请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (4.05 mM); Clear solution
请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (4.05 mM); Suspended solution; Need ultrasonic
请依序添加每种溶剂： 10% EtOH 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.05 mM); Clear solution
请输入账号
请输入密码
请输验证码
以上信息由企业自行提供，信息内容的真实性、准确性和合法性由相关企业负责，制药网对此不承担任何保证责任。
温馨提示：为规避购买风险，建议您在购买产品前务必确认供应商资质及产品质量。
制药网